Galectin-3C Inhibits Tumor Growth and Enhances Bortezomib's Anticancer Activity in Multiple Myeloma
Author Information
Author(s): Leonardo Mirandola, Yuefei Yu, Kitty Chui, Marjorie R. Jenkins, Everardo Cobos, Constance M. John, Maurizio Chiriva-Internati
Primary Institution: Texas Tech University Health Sciences Center
Hypothesis
Can galectin-3C serve as an effective treatment for multiple myeloma, particularly in combination with bortezomib?
Conclusion
Galectin-3C alone and in combination with bortezomib significantly inhibited tumor growth in a mouse model of multiple myeloma.
Supporting Evidence
- Galectin-3C was shown to inhibit the growth of multiple myeloma tumors in mice.
- The combination of galectin-3C and bortezomib resulted in a 94% reduction in tumor volume compared to untreated controls.
- Galectin-3C enhanced the anticancer activity of bortezomib in vitro and in vivo.
- All nine human multiple myeloma cell lines tested expressed galectin-3.
- Galectin-3C treatment significantly reduced the proliferation of multiple myeloma cells.
Takeaway
This study shows that a special protein called galectin-3C can help stop cancer cells from growing and work better with a medicine called bortezomib to fight a type of blood cancer.
Methodology
The study used a murine model of human multiple myeloma, treating mice with galectin-3C and bortezomib, and measuring tumor volumes over time.
Limitations
The study was conducted in a mouse model, which may not fully replicate human responses.
Participant Demographics
NOD/SCID mice were used in the study.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website